Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

229
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
229
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

813
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
813
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

401
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome" [Multiple Sclerosis and Related Disorders 112 (2026) 107312].

Multiple sclerosis and related disorders·2026
Same author

The contribution of trapezius and sternocleidomastoideus motor evoked potentials in the diagnosis of Amyotrophic lateral sclerosis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Socioeconomic status in Behçet's syndrome.

Clinical and experimental rheumatology·2026
Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026
Same author

A Pre-symptomatic phase of tumefactive multiple sclerosis mirrors radiologically isolated syndrome.

Multiple sclerosis and related disorders·2026
Same author

Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact.

Annals of clinical and translational neurology·2026

Related Experiment Video

Updated: Aug 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Ocrelizumab in pediatric multiple sclerosis.

Ceren Bibinoğlu Amirov1, Sema Saltık1, Cengiz Yalçınkaya2

  • 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pediatrics, Division of Child Neurology, Istanbul, Turkey.

European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
|February 1, 2023
PubMed
Summary
This summary is machine-generated.

Ocrelizumab significantly reduced relapse rates and MRI activity in pediatric relapsing-remitting multiple sclerosis (P-RRMS) patients. This study indicates Ocrelizumab is a safe and effective treatment for highly active P-RRMS.

More Related Videos

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.1K
Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
08:05

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

9.3K

Related Experiment Videos

Last Updated: Aug 12, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.1K
Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
08:05

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

9.3K

Area of Science:

  • Neuroimmunology
  • Pediatric Neurology
  • Clinical Pharmacology

Background:

  • Ocrelizumab is an anti-CD20 monoclonal antibody approved for adult multiple sclerosis (MS).
  • Limited data exist on Ocrelizumab's efficacy and safety in pediatric MS cases.
  • Pediatric relapsing-remitting MS (P-RRMS) requires effective disease-modifying treatments.

Purpose of the Study:

  • To evaluate the efficacy and safety of Ocrelizumab in pediatric relapsing-remitting MS (P-RRMS) patients.
  • To assess changes in annualized relapse rate (ARR) and MRI activity.
  • To determine the safety profile and disability progression in young MS patients treated with Ocrelizumab.

Main Methods:

  • Retrospective analysis of 10 P-RRMS patients under 18 years old treated with Ocrelizumab for over 12 months.
  • Primary endpoints: ARR and MRI activity (T2 lesions, Gd-enhancing lesions).
  • Secondary endpoints: Relapse-free status, Expanded Disability Status Scale (EDSS), and safety.

Main Results:

  • Ocrelizumab treatment led to a significant decrease in mean ARR from 2.01 to 0 (P < 0.0001).
  • No MRI activity (new T2 lesions or Gd-enhancing lesions) was observed during treatment.
  • Mean EDSS scores improved from 1.75 to 1.20 (P = 0.024), with one case of anaphylaxis reported.

Conclusions:

  • Ocrelizumab demonstrates significant efficacy in reducing relapses and MRI activity in pediatric MS.
  • The treatment is associated with improved disability scores and a generally favorable safety profile.
  • Ocrelizumab is a safe and effective therapeutic option for highly active pediatric relapsing-remitting MS.